



Breast cancer treatment option with surface guidance now available for clinical use in U.S.

C-RAD continues to advance treatment capabilities focused on breast cancer treatment by collaborating with Accuray on their new VitalHold™ Breast Solution for the Radixact® System. The VitalHold technology will be available to clinics and their patients in the United States and European Union as well as other regions, subject to regulatory clearance or approvals.*

The Accuray VitalHold Breast Solution facilitates deep inspiration breath hold (DIBH) treatments using the Radixact System's fixed beam angle delivery mode (TomoDirect™) and a fully integrated and automated surface-guided radiation therapy (SGRT) system, featuring the Catalyst+ HD system from C-RAD.

SGRT is designed to enable cancer care teams to effectively position the patient and confidently monitor the accuracy of that positioning throughout treatment.

VitalHold with Catalyst+ HD offers radiation oncology departments a seamless workflow that allows DIBH treatments on the Radixact System to minimize radiation dose to organs at risk and reduce associated complications later in life. The solution also offers seamless integration to ensure the highest level of accuracy and efficiency to potentially shorten treatment slots, with fewer errors, greater patient comfort and a less disruptive patient experience.

"C-RAD is incredibly proud of our collaboration with Accuray. Together, we have created a comprehensive breast cancer treatment toolset providing the ability to treat the full spectrum of breast cases," said Cecilia de Leeuw, CEO and President of C-RAD AB. "VitalHold is a powerful application of C-RAD's proven SGRT technology — and one that's sure to touch the lives of countless breast cancer patients."

*Accuray Incorporated (NASDAQ: ARAY) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its VitalHold™ breast package on the Radixact® System. The treatment option will also be available in the EU market.

VitalHold™, TomoDirect™ and Radixact® are trademarks and registered trademarks of Accuray.

For further information:

Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, investors@c-rad.com
Christoffer Herou, CFO, +46 (0)725 82 86 16, investors@c-rad.com

Press Release
14 August 2023 09:15:00 CEST



About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit <http://www.c-rad.com>

Attachments

[Breast cancer treatment option with surface guidance now available for clinical use in U.S.](#)